WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): February 8, 2006

                               CYTOGEN CORPORATION

               (Exact Name of Registrant as Specified in Charter)

       Delaware                       000-14879                  22-2322400
----------------------------  -------------------------      -------------------
(State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
   of Incorporation)                                         Identification No.)

  650 College Road East, CN 5308, Suite 3100, Princeton, NJ         08540
-------------------------------------------------------------  -----------------
                  (Address of Principal Executive Offices)        (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200

          (Former Name or Former Address, if Changed Since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written  communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))


     On  February  8,  2006,   Cytogen   Corporation   ("Cytogen")  and  Savient
Pharmaceuticals, Inc. ("Savient") announced the execution of a binding letter of
intent to negotiate a definitive  agreement granting Cytogen exclusive marketing
rights for SOLTAMOX(TM)  (tamoxifen citrate) in the United States.  SOLTAMOX,  a
cytostatic  estrogen  receptor  antagonist,  is the first oral  liquid  hormonal
therapy  approved in the U.S. It is indicated for the treatment of breast cancer
in adjuvant and  metastatic  settings and to reduce the risk of breast cancer in
women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.

     Under the terms of the final transaction,  Cytogen will pay to Savient upon
closing  an  upfront  licensing  fee of $2  million  and  additional  contingent
sales-based milestone payments of up to a total of $4 million. Savient will also
receive   royalties   on  net   sales  of   SOLTAMOX.   Additionally,   Rosemont
Pharmaceuticals Ltd.  ("Rosemont"),  a wholly owned subsidiary of Savient,  will
enter into a supply  agreement  with Cytogen for the  manufacture  and supply of
SOLTAMOX. Consummation of the transaction, which has been approved by the boards
of directors of both companies, is subject to a number of conditions,  including
satisfactory  completion  of  due  diligence  by  Cytogen  and  negotiation  and
execution of definitive licensing and supply agreements by Cytogen,  Savient and

     These matters were  announced in a press release  issued  February 8, 2006,
which is attached hereto as Exhibit 99.1.


(c) Exhibits.

          Exhibit No.      Description
          -----------      -----------

             99.1          Press  Release  of Cytogen  Corporation  and  Savient
                           Pharmaceuticals, Inc. dated February 8, 2006


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        CYTOGEN CORPORATION

                                        By:/s/ Michael D. Becker
                                           Michael D. Becker
                                           President and Chief Executive Officer

Dated:   February 8, 2006

                                  EXHIBIT INDEX

          Exhibit No.      Description
          -----------      -----------

             99.1          Press  Release  of Cytogen  Corporation  and  Savient
                           Pharmaceuticals, Inc. dated February 8, 2006